$AKBA With Otsuka having to give milestone and commercialization payments, why would they not throw dow a buyout offer right now for $3.50 to $4.50 per share and own 100% of the drug rights and profits in the USA, there is no guarantee of approval, so it would be extremely difficult to legally challenge their buyout off. They would spend 785 million on a $4.50 per share buyout vs spending at least another 250 million on commercialization, milestone payments and etc. Seems like it would be more beneficial to them at this time, given the low share price.
5
2
2 Likes